Silexion Therapeutics (SLXN) Interest Expenses (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Interest Expenses of $58000.0 for Q1 2026, down 31.76% year-over-year from $85000.0 in Q1 2025, and up 127.1% quarter-over-quarter from -$214000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Interest Expenses (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $58000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 31.76% year-over-year to $58000.0; the TTM figure through Mar 2026 stood at $30000.0 (up 160.0% YoY), while the FY2025 annual figure was $9.9 million, up 42.79% from the prior year.
- Interest Expenses for Q1 2026 stood at $58000.0, up from -$214000.0 in the prior quarter.
- The five-year high for Interest Expenses was $3.8 million in Q3 2024, with the low at -$4.1 million in Q4 2024.
- The 4-year median for Interest Expenses is $96500.0 (2024), against an average of $78916.7.
- Peak annual rise in Interest Expenses reached 5208.33% in 2024, while the deepest fall reached 1578.18% in 2024.
- Silexion Therapeutics' Interest Expenses stood at $275000.0 in 2023, then slumped by 1578.18% to -$4.1 million in 2024, then soared by 94.74% to -$214000.0 in 2025, then soared by 127.1% to $58000.0 in 2026.
- Business Quant data shows SLXN's Interest Expenses at $58000.0 in Q1 2026, -$214000.0 in Q4 2025, and -$30000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129,000.00 |
| Jun 30, 2026 | -129,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Dec 31, 2025 | -214,000.00 |
| Dec 31, 2025 | -214,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | -4.07 Mn |
| Dec 31, 2024 | -4.07 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Mar 31, 2024 | 168,000.00 |